Wednesday, April 25, 2018

BRIEF-European Commission Approves Bristol-Myers Squibb's Opdivo 4-Week Dosing Schedule

* EUROPEAN COMMISSION APPROVES BRISTOL-MYERS SQUIBB’S OPDIVO (NIVOLUMAB) FOUR-WEEK DOSING SCHEDULE FOR ADVANCED MELANOMA AND PREVIOUSLY TREATED RENAL CELL CARCINOMA Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)

No comments: